Trial Profile
TWIST. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2014
Price :
$35
*
At a glance
- Drugs Interferon alpha-2a (Primary) ; Temsirolimus
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms TWIST
- 05 Jul 2011 New trial record